Iovance Biotherapeutics Stock Hits Multi-Year High on Raised 2026 Revenue Guidance

Key Facts

1Iovance Biotherapeutics raised its full-year 2026 revenue guidance to $420 million.

2The company's stock reached its highest level since 2024 as analysts cheered the updated guidance.

Iovance Biotherapeutics raised its full-year 2026 revenue guidance to $420 million. Seeking Alpha reported that the company's stock reached its highest level since 2024 following the update, as analysts cheered the revised financial targets.

The upward revision triggered a rally of more than 30% in the stock during trading on Tuesday, September 29, 2026. This increase in revenue outlook suggests stronger-than-expected commercial performance or market adoption of the company's therapies, bolstering investor confidence in its long-term growth trajectory.